Bronchodilators
Bronchodilators - Related Videos
01:26
COPD: Management Using Bronchodilators and Corticosteroids
0 Views •
2024
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
0 Views •
Cited by 4 •
2010
Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
0 Views •
Cited by 11 •
2017
The inhalation unit described herein can generate, sample for characterization, and uniformly deposit a drug aerosol in the lungs of rodents. This enables the pre-clinical determination of the efficacy and safety of drug doses deposited in the lungs; key data enabling clinical inhaled drug development.
13:10
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
0 Views •
Cited by 130 •
2013
The present protocol provides a detailed step-by-step description of the procedures required to execute measurements of respiratory system mechanics as well as the assessment of airway responsiveness to inhaled methacholine in mice using the forced oscillation technique (flexiVent; SCIREQ Inc, Montreal, Qc, Canada).
FAQs
Beta2-adrenergic agonists act by increasing cyclic AMP within airway smooth muscle. This intracellular change promotes relaxation, which widens the bronchi and improves airflow. Their mechanism explains why they are central to bronchodilator therapy and why drugs in this class can be selected when rapid or sustained improvement in airflow is needed.
Anticholinergic agents work by blocking muscarinic signaling, a pathway that promotes bronchoconstriction. Beta2-adrenergic agonists instead increase cyclic AMP to relax airway smooth muscle. Because these drug classes influence different signaling mechanisms, their pharmacologic distinctions help guide individualized treatment according to the patient's respiratory condition and the desired pattern of airway control.
Methylxanthines can enhance bronchodilation by inhibiting phosphodiesterase activity. This mechanism differs from both beta2-adrenergic stimulation and muscarinic blockade, adding a separate pharmacologic route for supporting airway opening. Their distinct mechanism is important when comparing bronchodilator classes and considering how different drugs may contribute to the management of airflow limitation.
Duration determines whether a medication is suited to immediate symptom relief or ongoing control. Short-acting bronchodilators provide rapid relief of bronchospasm, whereas long-acting agents help maintain airway opening. Matching the drug's duration with the clinical need allows treatment to address sudden worsening differently from persistent airflow limitation.
Bronchodilators support symptom control in asthma, chronic obstructive pulmonary disease, and other conditions involving reversible or persistent airflow limitation. Their use is relevant when narrowing of the airways contributes to impaired airflow. The underlying pattern of limitation, together with the desired duration of effect, helps determine the most appropriate pharmacologic approach.
Selection requires considering both how a drug opens the airways and how its adverse effects may affect treatment. Beta2-adrenergic agonists, anticholinergic agents, and methylxanthines act through different mechanisms, while short- and long-acting formulations serve different purposes. These differences support individualized treatment rather than applying one bronchodilator strategy to every patient.